ABLYNX - Nanobodies - Turnarond on the Horizon!
Partnering of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX) and its nanobody platform’s’ potential in the limelight! Though ABLX suffered from several setbacks in 2011, strategic decisions on prioritizing its proprietary drugs in the pipeline and discovery alliances with Novartis and Merck KGaA helped in restoring investors confidence in ABLX and its technology platform. ABLX drug portfolio is a blend of validated and novel targets some of which are unpartnered. In anticipation of. For more detail, please read our report on ABLX, released on Oct. 3, 2013, titled, 'Nanobodies - Turnarond on the Horizon!'
